Geriatrics Section, Department of Internal Medicine and Geriatrics, University of Palermo, via del Vespro, 141, 90127, Palermo, Italy.
MRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, UK.
Drugs. 2022 Sep;82(13):1347-1355. doi: 10.1007/s40265-022-01773-5. Epub 2022 Sep 16.
Knee osteoarthritis (OA) is one of the most common and disabling medical conditions. In the case of moderate to severe pain, a single intervention may not be sufficient to allay symptoms and improve quality of life. Examples include first-line, background therapy with symptomatic slow-acting drugs for OA (SYSADOAs) or non-steroidal anti-inflammatory drugs (NSAIDs). Therefore, the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) performed a review of a multimodal/multicomponent approach for knee OA therapy. This strategy is a particularly appropriate solution for the management of patients affected by knee OA, including those with pain and dysfunction reaching various thresholds at the different joints. The multimodal/multicomponent approach should be based, firstly, on different combinations of non-pharmacological and pharmacological interventions. Potential pharmacological combinations include SYSADOAs and NSAIDs, NSAIDs and weak opioids, and intra-articular treatments with SYSADOAs/NSAIDs. Based on the available evidence, most combined treatments provide benefit beyond single agents for the improvement of pain and other symptoms typical of knee OA, although further high-quality studies are required. In this work, we have therefore provided new, patient-centered perspectives for the management of knee OA, based on the concept that a multimodal, multicomponent, multidisciplinary approach, applied not only to non-pharmacological treatments but also to a combination of the currently available pharmacological options, will better meet the needs and expectations of patients with knee OA, who may present with various phenotypes and trajectories.
膝骨关节炎(OA)是最常见和最致残的医学病症之一。对于中重度疼痛患者,单一干预措施可能不足以缓解症状和改善生活质量。例如,一线、背景治疗,即使用治疗 OA 的症状缓解慢作用药物(SYSADOAs)或非甾体抗炎药(NSAIDs)。因此,欧洲临床和经济骨质疏松、骨关节炎和肌肉骨骼疾病学会(ESCEO)对膝骨关节炎治疗的多模式/多组分方法进行了回顾。对于膝骨关节炎患者的管理,这种策略是一种特别合适的解决方案,包括那些疼痛和功能障碍达到不同关节不同阈值的患者。多模式/多组分方法应首先基于非药物和药物干预的不同组合。潜在的药物组合包括 SYSADOAs 和 NSAIDs、NSAIDs 和弱阿片类药物,以及关节内 SYSADOAs/NSAIDs 治疗。基于现有证据,大多数联合治疗在改善膝骨关节炎的疼痛和其他症状方面提供了优于单一药物的益处,尽管需要进一步的高质量研究。在这项工作中,我们基于多模式、多组分、多学科方法的概念,为膝骨关节炎的管理提供了新的、以患者为中心的观点,该方法不仅应用于非药物治疗,还应用于当前可用的药物选择的联合治疗,将更好地满足具有各种表型和轨迹的膝骨关节炎患者的需求和期望。